Synaptic Plasticity Pathway plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Synaptic plasticity refers to the ability of synaptic connections to strengthen or weaken over time in response to activity patterns. This fundamental cellular mechanism underlies learning, memory, and cognitive function. In neurodegenerative diseases, synaptic dysfunction represents one of the earliest and most critical pathological features, often preceding neuronal loss by years or even decades. [1]
The study of synaptic plasticity has revealed that synapses are not static structures but dynamic elements that continuously adapt their strength, structure, and molecular composition in response to neural activity, experience, and disease processes. [2]
Long-term potentiation is a persistent activity-dependent strengthening of synaptic connections that is widely considered the cellular basis for learning and memory. LTP occurs through several phases: [3]
Late-Phase LTP (L-LTP) [5]
Long-term depression is an activity-dependent weakening of synaptic strength that is essential for synaptic homeostasis and learning: [6]
NMDA Receptor-Dependent LTD [7]
Metabotropic Glutamate Receptor (mGluR)-Dependent LTD [8]
Dendritic spines are small protrusions from dendrites that receive the majority of excitatory synaptic inputs. Their morphology is highly dynamic: [9]
Spine dynamics are regulated by: [10]
Amyloid-beta (Aβ) peptides, the primary component of amyloid plaques in Alzheimer's disease, have profound effects on synaptic plasticity: [11]
Presynaptic Effects
Postsynaptic Effects
Oligomeric Aβ as the Synaptotoxic Species
Tau protein pathology disrupts synaptic plasticity through multiple mechanisms:
LTP Impairment
LTD Enhancement
Structural Changes
The nigrostriatal dopamine system critically regulates synaptic plasticity in the basal ganglia:
D1 Receptor-Mediated Plasticity
D2 Receptor-Mediated Plasticity
Alpha-synuclein (αSyn) pathology directly impacts synaptic plasticity:
Presynaptic Effects
Synaptic Plasticity Dysregulation
The dorsal striatum shows characteristic plasticity changes in PD:
Disease-Modifying Approaches
Symptomatic Treatments
The study of Synaptic Plasticity Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications advancing opubmed.ncbi.nlm.nih.gov/38811309/)
Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health. (2024) — Curr Pharm Des PMID:38303529
A small TAT-TrkB peptide prevents BDNF receptor cleavage and restores synaptic physiology in Alzheimer's disease. (2024) — Mol Ther PMID:39205389
Microglial lipid phosphatase SHIP1 limits complement-mediated synaptic pruning in the healthy developing hippocampus. (2025) — Immunity PMID:39657671
The potential therapeutic role of itaconate and mesaconate on the detrimental effects of LPS-induced neuroinflammation in the brain. (2024) — J Neuroinflammation PMID:39164713
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 12 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 34%
Malenka RC, Bear MF. 'LTP and LTD: an embarrassment of riches'. Neuron. 2004. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎
Henley JM, Wilkinson KA. Synaptic AMPA receptor composition in development, plasticity and disease. Nat Rev Neurosci. 2016. ↩︎
Huganir RL, Nicoll RA. 'AMPARs and synaptic plasticity: the last 25 years'. Neuron. 2013. ↩︎
Dumitriu D, Hyman BT, Spires-Jones TL. Synaptic alterations in Alzheimer's disease. Brain Res. 2012. ↩︎
Calabresi P, Picconi B, Parnetti L, Di Filippo M. [ A convergent model for cognitive dysfunctions in Parkinson's disease](https://doi.org/10.1016/S1474-4422(06). Lancet Neurol. 2006. ↩︎
Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010. ↩︎
Hardy J, Selkoe DJ. 'The amyloid hypothesis of Alzheimer''s disease: progress and problems on the road to therapeutics'. Science. 2002. ↩︎
Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004. ↩︎
Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007. ↩︎
Citri A, Malenka RC. 'Synaptic plasticity: multiple forms, functions, and mechanisms'. Neuropsychopharmacology. 2008. ↩︎